1.18
price down icon6.35%   -0.08
after-market Handel nachbörslich: 1.23 0.05 +4.24%
loading
Schlusskurs vom Vortag:
$1.26
Offen:
$1.28
24-Stunden-Volumen:
8.82M
Relative Volume:
10.59
Marktkapitalisierung:
$117.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-292.19M
KGV:
-0.2599
EPS:
-4.54
Netto-Cashflow:
$-208.41M
1W Leistung:
-9.23%
1M Leistung:
-1.67%
6M Leistung:
-61.44%
1J Leistung:
-71.90%
1-Tages-Spanne:
Value
$1.16
$1.285
1-Wochen-Bereich:
Value
$1.16
$1.39
52-Wochen-Spanne:
Value
$1.01
$5.44

Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile

Name
Firmenname
Zentalis Pharmaceuticals Inc
Name
Telefon
(858) 263-4333
Name
Adresse
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Name
Mitarbeiter
166
Name
Twitter
@ZentalisP
Name
Nächster Verdiensttermin
2025-03-26
Name
Neueste SEC-Einreichungen
Name
ZNTL's Discussions on Twitter

Vergleichen Sie ZNTL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ZNTL
Zentalis Pharmaceuticals Inc
1.18 117.28M 0 -292.19M -208.41M -4.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-12 Hochstufung Wedbush Underperform → Neutral
2024-06-20 Herabstufung UBS Buy → Neutral
2024-06-18 Herabstufung Jefferies Buy → Hold
2024-06-18 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-06-18 Herabstufung Wedbush Neutral → Underperform
2024-06-18 Herabstufung Wells Fargo Overweight → Equal Weight
2023-11-08 Herabstufung Wedbush Outperform → Neutral
2023-11-07 Herabstufung Leerink Partners Outperform → Market Perform
2022-07-12 Eingeleitet Cowen Outperform
2022-04-06 Eingeleitet Wells Fargo Overweight
2021-10-07 Fortgesetzt Jefferies Buy
2021-09-30 Eingeleitet Stifel Buy
2021-09-29 Eingeleitet Oppenheimer Outperform
2021-05-21 Eingeleitet UBS Buy
2021-01-20 Eingeleitet Wedbush Outperform
2020-09-29 Eingeleitet Cantor Fitzgerald Overweight
2020-08-27 Eingeleitet H.C. Wainwright Buy
2020-04-28 Eingeleitet Guggenheim Buy
2020-04-28 Eingeleitet Jefferies Buy
2020-04-28 Eingeleitet Morgan Stanley Overweight
2020-04-28 Eingeleitet SVB Leerink Outperform
Alle ansehen

Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten

pulisher
Jun 18, 2025

Zentalis Pharmaceuticals shareholders elect three directors at annual meeting - Investing.com

Jun 18, 2025
pulisher
Jun 17, 2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Brokerages - Defense World

Jun 17, 2025
pulisher
Jun 12, 2025

Wealth Enhancement Advisory Services LLC Raises Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Bank of America Corp DE - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Squarepoint Ops LLC Reduces Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Ameriprise Financial Inc. Purchases New Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies - The Globe and Mail

Jun 05, 2025
pulisher
Jun 05, 2025

ProShare Advisors LLC Lowers Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Nuveen Asset Management LLC Has $1.94 Million Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Deutsche Bank AG Grows Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Two Sigma Investments LP Sells 291,801 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ZNTL Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

Zentalis Expands Cancer Research Team: 137K Share Options Granted to Key New Hires - Stock Titan

Jun 02, 2025
pulisher
Jun 01, 2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Acquired by Millennium Management LLC - Defense World

Jun 01, 2025
pulisher
May 28, 2025

Northern Trust Corp Raises Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

May 28, 2025
pulisher
May 25, 2025

BNP Paribas Financial Markets Invests $534,000 in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

May 25, 2025
pulisher
May 23, 2025

Captrust Financial Advisors Buys New Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

May 23, 2025
pulisher
May 23, 2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Analysts - Defense World

May 23, 2025
pulisher
May 23, 2025

Jane Street Group LLC Boosts Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

May 23, 2025
pulisher
May 20, 2025

Zentalis Pharmaceuticals at H.C. Wainwright BioConnect Conference - TipRanks

May 20, 2025
pulisher
May 19, 2025

Balyasny Asset Management L.P. Has $175,000 Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

May 19, 2025
pulisher
May 19, 2025

Wedbush Issues Optimistic Outlook for ZNTL Earnings - Defense World

May 19, 2025
pulisher
May 17, 2025

Wedbush Reaffirms Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World

May 17, 2025
pulisher
May 16, 2025

Zentalis Pharmaceuticals First Quarter 2025 Earnings: US$0.67 loss per share (vs US$0.14 profit in 1Q 2024) - Yahoo Finance

May 16, 2025
pulisher
May 16, 2025

Zentalis Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks

May 16, 2025
pulisher
May 15, 2025

ZNTL Advances Azenosertib Development Amid Strategic Progress | - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Analyst Reiterates Neutral Rating for Zentalis Pharma (ZNTL) | Z - GuruFocus

May 15, 2025
pulisher
May 15, 2025

ZNTL: Oppenheimer Adjusts Price Target Amid Regulatory Developme - GuruFocus

May 15, 2025
pulisher
May 15, 2025

ZNTL: Oppenheimer Adjusts Price Target Amid Regulatory Developments | ZNTL Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Zentalis Pharma (ZNTL) Receives Buy Rating from HC Wainwright & Co. | ZNTL Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

22,440 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Bought by Raymond James Financial Inc. - Defense World

May 15, 2025
pulisher
May 14, 2025

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Zentalis Pharmaceuticals Inc (ZNTL) Q1 2025 Earnings: EPS Misses at -$0.67, Revenue Meets Estimate at $0.00 Million - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Zentalis Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025
pulisher
May 11, 2025

Barclays PLC Grows Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

May 11, 2025
pulisher
May 02, 2025

An analyst sees good growth prospects for Zentalis Pharmaceuticals Inc (ZNTL) - Sete News

May 02, 2025
pulisher
May 02, 2025

Zentalis Pharmaceuticals Inc expected to post a loss of 64 cents a shareEarnings Preview - TradingView

May 02, 2025
pulisher
May 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ZNTL Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 01, 2025
pulisher
May 01, 2025

Zentalis Expands Cancer Drug Development Team with Strategic New Hire Grant Worth $20,000 - Stock Titan

May 01, 2025
pulisher
May 01, 2025

Was anything positive for Zentalis Pharmaceuticals Inc (ZNTL) stock last session? - uspostnews.com

May 01, 2025
pulisher
May 01, 2025

Zentalis Pharmaceuticals Inc [ZNTL] Director makes an insider purchase of 21,000 shares worth 29373.0. - knoxdaily.com

May 01, 2025
pulisher
May 01, 2025

Zentalis pharmaceuticals director Scott Myers acquires $29,372 in stock By Investing.com - Investing.com Canada

May 01, 2025
pulisher
Apr 30, 2025

Zentalis pharmaceuticals director Scott Myers acquires $29,372 in stock - Investing.com Australia

Apr 30, 2025
pulisher
Apr 29, 2025

Levi & Korsinsky Reminds Zentalis Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsZNTL - ACCESS Newswire

Apr 29, 2025
pulisher
Apr 29, 2025

Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock - Yahoo Finance

Apr 29, 2025
pulisher
Apr 29, 2025

Ratios Revealed: Decoding Zentalis Pharmaceuticals Inc (ZNTL)’s Financial Health - DWinneX

Apr 29, 2025
pulisher
Apr 29, 2025

Zentalis shares insights on cancer research at AACR - Investing.com Australia

Apr 29, 2025
pulisher
Apr 29, 2025

Zentalis (ZNTL) Advances with Phase 2 Trial in Ovarian Cancer | - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Zentalis shares insights on cancer research at AACR By Investing.com - Investing.com Canada

Apr 29, 2025

Finanzdaten der Zentalis Pharmaceuticals Inc-Aktie (ZNTL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Zentalis Pharmaceuticals Inc-Aktie (ZNTL) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Bruns Ingmar
Chief Medical Officer
Feb 06 '25
Buy
2.28
20,000
45,656
36,629
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Kapitalisierung:     |  Volumen (24h):